GeoVax Labs, Inc. — FY2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019; filed March 24, 2020. This is an annual report, not a quarterly filing. GeoVax is a clinical-stage biotechnology company developing vaccines and immunotherapies using its GV-MVA-VLP platform. It had no product sales and relied on government grants, collaborations, and equity financing.
Financial performance and liquidity
| Metric (USD) | 2019 | 2018 |
|---|---|---|
| Grant and collaboration revenue | $1,175,896 | $963,203 |
| Research and development expense | $1,910,715 | $1,878,652 |
| General and administrative expense | $1,637,674 | $1,647,268 |
| Operating loss | $(2,372,493) | $(2,562,717) |
| Net loss | $(2,370,629) | $(2,560,094) |
| Net cash used in operating activities | $(1,398,497) | $(1,543,026) |
| Cash and cash equivalents, year-end | $283,341 | $259,701 |
| Total assets, year-end | $468,880 | $642,064 |
| Total liabilities, year-end | $2,043,436 | $1,664,411 |
- Revenue increased year over year, principally from government grants; grants contributed $983,682 in 2019 and collaborations $192,214. No revenue came from product sales. The filing does not provide a conventional product gross margin.
- Net loss narrowed from 2018, while operating expenses were broadly stable. Research and development spending rose 1.7%; general and administrative expense excluding stock-based compensation rose 11%, mainly due to special stockholder meetings and reverse-split costs.
- Working capital deficit was $1,568,929, versus $1,005,127 at year-end 2018. Stockholders’ equity deficiency was $1,574,556. The company had $39,743 of notes payable, including $12,500 current.
- Accrued management salaries and director fees totaled $1,732,702 at year-end. Management and directors deferred compensation to conserve cash; management salary deferrals were expected to continue at about $31,800 per month.
- Financing activities provided $1,429,743 in 2019, including $1.44 million of net preferred-stock proceeds. The company reported $1,605,505 of remaining approved grant funds for 2020, of which it expected $1,053,776 to reimburse third-party services.
- The reported loss per common share was $(39.25) for 2019 and $(15,610.33) for 2018. The filing retroactively restates share and per-share data for reverse stock splits, so these figures warrant careful review before comparison.
Changes, developments, and outlook
- Revenue rose from $963,203 to $1,175,896, while net loss decreased from $2,560,094 to $2,370,629. Operating cash use also declined year over year.
- The most advanced program was preventive HIV vaccine GOVX-B11. A further HVTN Phase 1 trial, HVTN 132, was planned to begin enrollment in late 2020; the filing also anticipated 2020 Phase 1 studies with collaborators AGT and UCSF for HIV treatment/remission approaches. These were expectations, not completed trials.
- In January 2020, GeoVax signed a letter of intent with China-based BravoVax to develop a COVID-19 vaccine. GeoVax said it had designed a construct and sought government funding; a definitive collaboration agreement was still pending.
- GeoVax reported preclinical protection results for Ebola, Marburg, Lassa, and Zika candidates, including 100% protection in specified animal challenge studies. These candidates remained preclinical; further development of several programs depended on additional funding or partners.
- In September 2019, the company formed wholly owned oncology subsidiary Immutak and began separate financing efforts for oncology programs.
- Management said existing cash, grant funding, clinical-trial support, and committed equity sources were expected to support planned operations only into the second quarter of 2020. Additional capital was required thereafter; management planned to pursue grants, collaborations, and securities offerings. No revenue or profitability guidance was provided.
Risks, contingencies, and unusual items
- Going concern: The independent auditor highlighted substantial doubt about GeoVax’s ability to continue as a going concern. The company had recurring losses, liabilities exceeding assets, and a need for additional financing. The financial statements contain no adjustments for a possible inability to continue operations.
- Dilution and financing: Convertible preferred stock had variable conversion-price terms, and conversions and subsequent share sales could materially dilute existing holders and pressure the share price. After year-end, a 1-for-2,000 reverse split took effect; preferred conversions through March 23, 2020 resulted in 13,481,079 common shares issued. The company also issued $300,000 of Series J preferred stock in January 2020, with a variable conversion price.
- Development and operating risks: All candidates were unapproved; clinical, regulatory, manufacturing, and commercialization success was uncertain. GeoVax relied on third-party manufacturers, collaborators, and government support, and had limited personnel and resources. Loss or reduction of grants or trial support could affect operations.
- COVID-19 uncertainty: The filing warned that the pandemic could disrupt employees, collaborators, facilities, clinical trials, manufacturing, and service providers. Its impact was uncertain as of the filing date.
- Other disclosures: The company reported no material legal proceedings and no material off-balance-sheet arrangements other than operating leases. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end; the auditor did not express an opinion on internal-control effectiveness.
Key facts for investors to verify
- Near-term cash runway, subsequent financing, and whether operations continued beyond the stated second-quarter 2020 funding horizon.
- Actual cash burn, grant drawdowns and reimbursement obligations, and the status of the $1.605 million remaining Lassa grant funds.
- Preferred-stock conversion terms, outstanding preferred shares and warrants, post-split share counts, and resulting dilution; reconcile the filing’s share and per-share figures across reverse splits.
- Whether the planned HIV trials began and what their funding, enrollment, and results were; also verify the status and terms of the BravoVax COVID-19 collaboration and funding applications.
- Progress from preclinical evidence to human testing, and the funding or partnering required to advance each vaccine and oncology program.